APA (7th ed.) Citation

Simpson, E. L., Silverberg, J. I., Prajapati, V. H., Eyerich, K., Katoh, N., Boguniewicz, M., . . . de Bruin-Weller, M. (2025). Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology & Therapy, 15(8), 2061. https://doi.org/10.1007/s13555-025-01443-w

Chicago Style (17th ed.) Citation

Simpson, Eric L., et al. "Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis." Dermatology & Therapy 15, no. 8 (2025): 2061. https://doi.org/10.1007/s13555-025-01443-w.

MLA (9th ed.) Citation

Simpson, Eric L., et al. "Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis." Dermatology & Therapy, vol. 15, no. 8, 2025, p. 2061, https://doi.org/10.1007/s13555-025-01443-w.